Linked Data API

Show Search Form

Search Results

1656996
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Vorasidenib more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) Servier and (b) the MHRA about making Vorasidenib available to clinically suitable brain tumour patients in the UK under the Early Access to Medicines Scheme more like this
tabling member constituency St Albans more like this
tabling member printed
Daisy Cooper more like this
uin 196642 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-09-06more like thismore than 2023-09-06
answer text <p>The Secretary of State and the Department have had no specific discussions with Servier about making Vorasidenib available to clinically suitable brain tumour patients in the United Kingdom under the Early Access to Medicines Scheme (EAMS).</p><p>The Medicines and Healthcare Products Regulatory Agency (MHRA) has also not had any specific discussions with the Secretary of State regarding Vorasidenib. The MHRA has not issued a scientific opinion for Vorasidenib under EAMS but should an application for this be received, the MHRA will consider this accordingly.</p> more like this
answering member constituency Colchester remove filter
answering member printed Will Quince more like this
question first answered
less than 2023-09-06T09:27:46.527Zmore like thismore than 2023-09-06T09:27:46.527Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4769
label Biography information for Daisy Cooper remove filter